Medicare now covers certain weight loss GLP-1 drugs through the Medicare GLP-1 Bridge, a demonstration program that started July 1, 2026 and charges eligible Part D enrollees a flat $50 monthly copay for a limited list of medications. Not every beneficiary qualifies, and not every drug is included. The sections below walk through exactly who’s eligible, what’s covered, and how to check your own status.
TL;DR:
- The program covers Foundayo, Wegovy (injection and tablet), and Zepbound KwikPen, with formulations and plan types that influence coverage eligibility.
- A provider must submit a clinical attestation and prior authorization, which remains valid until December 31, 2027, if approved and medication remains unchanged.
- The flat $50 copay does not count toward Medicare deductibles or out-of-pocket limits, and does not benefit from Extra Help or LIS subsidies.
- Beneficiaries with existing Part D coverage for GLP-1 drugs or outside the eligible plan types are ineligible, and alternative out-of-pocket telehealth programs are available.
Table of Contents
- What the Medicare GLP-1 Bridge covers: drugs, formulations, and eligible plan types
- Who is eligible: BMI cutoffs, qualifying conditions, age, and disqualifying diagnoses
- Provider requirements and prior-authorization steps beneficiaries should expect
- Costs and financial effects: the $50 copay and how the Bridge interacts with Part D accounting
- Exclusions and special cases beneficiaries should watch for
- Program timeline and what CMS is studying
- How to check your eligibility and the practical next steps to get coverage
- Potential side effects and safety considerations specific to weight-loss drugs covered by Medicare
- Guidance on alternative weight management strategies when coverage for weight-loss drugs is unavailable or limited
- What this looks like for beneficiaries and caregivers
- An out-of-pocket option when the Bridge doesn’t fit your situation
- FAQ
- Sources
What the Medicare GLP-1 Bridge covers: drugs, formulations, and eligible plan types
The Bridge is not a blanket expansion of Part D. It’s a separate payment pathway that sits outside normal Part D claims processing, built around a short, specific list of products. According to Medicare’s official coverage page, the program covers:
- Foundayo, in all available forms
- Wegovy, both the injection and the tablet formulation
- Zepbound, but only the KwikPen delivery device, not single-dose vials or pens
That last distinction matters. Two beneficiaries prescribed the same active ingredient could end up on opposite sides of the Bridge depending on which formulation their provider prescribes and which one the pharmacy has on hand. If you’re prescribed Zepbound, confirm with your pharmacist that the product is the KwikPen version before assuming it will be covered through the Bridge.
Because the Bridge operates outside the standard Part D payment flow, the usual mechanics of your drug plan, like formulary tiers, step therapy rules, or your plan’s own prior authorization criteria for weight loss drugs, don’t automatically apply. Instead, CMS runs a parallel set of clinical and administrative rules that every participating plan follows the same way, regardless of which Part D plan you’re enrolled in. That consistency is part of the point: CMS wants comparable data across plan types to evaluate the demonstration.
Eligible plan types include:
- Stand-alone Prescription Drug Plans (PDPs)
- Medicare Advantage plans with drug coverage (MA-PDs)
- Special Needs Plans (SNPs)
- Employer Group Waiver Plans (EGWPs)
- The Limited Income Newly Eligible Transition (LI NET) program
A handful of plan arrangements fall outside this list, which we’ll cover later. For now, the practical takeaway is that most people with standard Medicare drug coverage, through a stand-alone plan or a Medicare Advantage plan that includes drug benefits, are structurally eligible to participate, assuming they also meet the clinical criteria in the next section.
Who is eligible: BMI cutoffs, qualifying conditions, age, and disqualifying diagnoses
Eligibility for the Bridge runs through a combination of age, body mass index, and specific health conditions, outlined in the Medicare GLP-1 Bridge PDF explainer. You generally need to be a Medicare beneficiary enrolled in an eligible Part D plan type, and you need to fit one of three BMI-based pathways:
- A BMI of 35 or higher, regardless of other health conditions
- A BMI of 30 or higher combined with at least one qualifying comorbidity
- A BMI of 27 or higher with a history of specific vascular disease or prediabetes
If you’re unsure how your BMI is calculated, the NHLBI’s BMI calculator is a straightforward way to check before talking to your provider.
The qualifying comorbidities tied to the lower BMI thresholds include:
- Diastolic heart failure
- Uncontrolled hypertension
- Chronic kidney disease at stage 3a or beyond
- Prediabetes
- A prior heart attack or stroke
- Symptomatic peripheral artery disease
On the other side, certain conditions disqualify you from the Bridge specifically because Part D is already supposed to cover your GLP-1 for that diagnosis. If you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or metabolic dysfunction-associated steatohepatitis (MASH, formerly called NASH), your GLP-1 prescription likely falls under standard Part D coverage already, not the Bridge. Similarly, if your current Part D plan already covers a GLP-1 for your specific diagnosis, you stay on that path rather than switching over.
Plan type adds another layer of nuance. Even if you meet the clinical criteria, your specific plan’s participation and administrative rules can affect how smoothly your request moves forward. If anything in your situation feels ambiguous, your plan’s member services line or 1-800-MEDICARE can confirm your status directly. For a broader look at how clinical eligibility for GLP-1 therapy works outside Medicare specifically, our GLP-1 eligibility overview covers the general criteria providers use.
Provider requirements and prior-authorization steps beneficiaries should expect
Getting approved through the Bridge starts with your provider, not your pharmacy. Per CMS guidance for providers, your clinician needs to attest that you meet the clinical criteria and that you’re participating in an accompanying lifestyle program, which typically covers diet and activity counseling alongside the medication. Notably, the provider submitting this attestation doesn’t need to be Medicare-enrolled themselves to file a prior authorization for the Bridge.
CMS uses a single central processor to handle Bridge claims and adjudication in 2026, rather than routing them through each individual Part D plan’s usual process. That centralization is meant to keep the criteria consistent nationwide.
Here’s what to expect as the process unfolds:
- Your provider documents your BMI, relevant diagnoses, and lifestyle program enrollment as part of the clinical record supporting the request.
- Your provider or pharmacy submits the prior authorization, ideally electronically, since CMS strongly encourages electronic submission over fax for faster processing.
- You receive a written notice from Medicare confirming approval or denial, which also establishes your authorization window.
- If approved, your authorization stays valid through December 31, 2027, as long as you remain on the same drug. Switching medications triggers a new PA.
Pro Tip: Before your appointment, ask your pharmacy whether your specific drug and formulation will route through the Bridge or standard Part D, so your provider can document the right pathway from the start.
Gather your recent weight and BMI records, any documentation of the qualifying conditions listed earlier, and a list of your current medications before your visit. That preparation tends to shorten the back-and-forth between your provider’s office and the pharmacy once the PA is submitted.
Costs and financial effects: the $50 copay and how the Bridge interacts with Part D accounting
The Medicare GLP-1 Bridge sets a flat $50 monthly copay for a one-month supply of an eligible drug, and that amount stays the same no matter which phase of your Part D benefit you’re currently in, whether you’re still in your deductible, in the coverage gap, or past the catastrophic threshold.
That flat rate comes with a tradeoff worth understanding clearly:
- The $50 copay does not count toward your Part D deductible
- It does not count toward your True Out-of-Pocket (TrOOP) costs
- Extra Help, also called the Low-Income Subsidy (LIS), does not apply to Bridge copays
CMS has noted that participating manufacturers are supplying these drugs at negotiated net prices, and because the Bridge operates outside standard Part D accounting, your $50 payments won’t move you any closer to catastrophic coverage on your other medications. If you’re tracking your overall drug spending for the year, keep that separation in mind: Bridge payments and Part D payments run on two different ledgers.
If you don’t qualify for the Bridge at all, whether due to BMI, diagnosis, or plan type, cash-pay options exist outside Medicare entirely. Our breakdown of GLP-1 costs without insurance walks through what out-of-pocket pricing typically looks like for comparison.
Exclusions and special cases beneficiaries should watch for
A few scenarios trip people up more than any other part of this program. First, if you already have Part D coverage for a GLP-1 drug tied to a Part D-coverable diagnosis, such as type 2 diabetes, you’re not eligible for the Bridge. You stay on your existing Part D path, and if your plan isn’t covering it the way you expect, that’s a plan-level exception request, not a Bridge issue.
Formulation matters just as much as the drug name itself:
- Zepbound is covered only in the KwikPen form; single-dose vials and pens are explicitly excluded
- Always confirm the exact National Drug Code (NDC) and formulation with your pharmacy before assuming coverage
Certain plan types also sit outside the Bridge’s structure, including Programs of All-Inclusive Care for the Elderly (PACE). If you’re dual-eligible for Medicare and Medicaid, your situation can involve additional rules that vary by state, so it’s worth a direct conversation with your plan.
If you hit a wall anywhere in this process, your local State Health Insurance Assistance Program (SHIP) or 1-800-MEDICARE can help sort out appeals or unresolved eligibility questions before you give up on the Bridge entirely.
Program timeline and what CMS is studying
The Medicare GLP-1 Bridge is not a permanent benefit. It started on July 1, 2026, and is scheduled to run through December 31, 2027. CMS built it as a Section 402 demonstration, meaning its core purpose is to collect real utilization data that could inform permanent Part D policy changes down the line, potentially including broader models like BALANCE.
Because this is a demonstration rather than a settled rule, formularies and plan-specific policies around GLP-1 coverage can still shift. Medicare’s Open Enrollment period, running October 15 through December 7 each year, is the right window to review whether your plan’s coverage has changed and whether a different plan type might serve you better.
How to check your eligibility and the practical next steps to get coverage
Moving from “I think I might qualify” to an actual prescription takes a few concrete steps:
- Confirm your plan type. Check whether you’re on a PDP, MA-PD, SNP, EGWP, or LI NET plan, since these are the eligible categories for the Bridge.
- Check your current Part D coverage. If you’re already covered for a GLP-1 under Part D for a qualifying diagnosis, you don’t need the Bridge.
- Collect your BMI and medical records, including documentation of any qualifying comorbidities.
- Ask your provider to submit a prior authorization to the Bridge’s central processor, ideally electronically.
For official information, Medicare.gov/coverage/weight-loss-drugs is the primary source, and you can also call 1-800-MEDICARE (1-800-633-4227), TTY 1-877-486-2048, or reach out to your local SHIP office for personalized help. If you’re navigating a plan change around this at the same time, enrollment window guidance from Platinum Benefit Advisors covers special enrollment situations that might apply to your case.
At the pharmacy, once you’re approved, refills on the same drug don’t require a new prior authorization through December 31, 2027, unless you switch medications. That’s one less hurdle once you’re through the initial approval.
Potential side effects and safety considerations specific to weight-loss drugs covered by Medicare
GLP-1 medications covered under the Bridge, including Foundayo, Wegovy, and Zepbound, carry the same general safety profile associated with this drug class regardless of how they’re paid for. Common side effects tend to include nausea, vomiting, diarrhea, constipation, and decreased appetite, often most noticeable when starting treatment or increasing dose.
More serious risks can include pancreatitis, gallbladder problems, and kidney issues, particularly in people who become dehydrated from persistent vomiting or diarrhea. These medications also carry specific warnings for people with a personal or family history of certain thyroid tumors, which is part of why provider oversight matters throughout treatment, not just at the point of prescribing.
Because Medicare eligibility for the Bridge is tied to specific comorbidities like heart failure, chronic kidney disease, or a prior stroke, it’s worth having an honest conversation with your provider about how a GLP-1 might interact with your existing conditions and other medications. Dose adjustments are common in the first few months as your body adjusts, and ongoing monitoring, rather than a one-time prescription, is the standard of care for anyone starting this class of drug.
Guidance on alternative weight management strategies when coverage for weight-loss drugs is unavailable or limited
If you don’t meet the Bridge’s BMI or comorbidity criteria, or your plan type falls outside the eligible categories, medication isn’t the only avenue worth pursuing. Structured lifestyle programs, including medically supervised nutrition counseling and physical activity plans, remain a foundational part of weight management regardless of medication access, and some Medicare plans cover obesity-related behavioral counseling separately from drug benefits.
Bariatric surgery is another path some beneficiaries pursue, and Medicare coverage for certain bariatric procedures already exists outside the Bridge program, with its own separate eligibility criteria tied to BMI and related health conditions.
For those considering medication outside of Medicare’s rules entirely, out-of-pocket GLP-1 programs are available, though they come with a different cost structure than the Bridge’s flat copay. Whatever path you choose, coordinating with your primary care provider keeps your weight management plan aligned with your other health conditions, especially if you’re managing heart disease, kidney issues, or diabetes alongside your weight.
What this looks like for beneficiaries and caregivers
A flat $50 copay is a relief for a lot of families who’ve been pricing out GLP-1 medications on their own. That part of the Bridge is genuinely good news. The paperwork side is less exciting: gathering BMI documentation, chasing down prior authorization confirmations, and figuring out whether your specific Zepbound formulation qualifies can feel like a second job some weeks.
Keep copies of everything your provider submits, and don’t assume your pharmacy and your provider’s office are always talking to each other in real time. A quick phone call to confirm a claim actually routed through the Bridge, rather than assuming it did, can save a frustrating billing surprise later. If you haven’t started the process yet, the checklist in the “How to check your eligibility” section above is the place to begin.
— Bryan
An out-of-pocket option when the Bridge doesn’t fit your situation
Not everyone will meet the Bridge’s BMI thresholds, comorbidity list, or plan-type requirements, and for those readers, a telehealth path outside Medicare is worth knowing about. We offer an online GLP-1 program for adults interested in starting treatment outside of prior authorization timelines or insurance eligibility rules.
Our process starts with an online provider assessment, and from there we prescribe GLP-1 medications, including both injection and tablet options, shipped directly to you. We don’t charge membership fees, and every plan includes provider visits plus ongoing coaching throughout your treatment. This is explicitly an out-of-pocket alternative: using our program doesn’t affect your Medicare eligibility, your Part D coverage, or your standing with the Bridge demonstration in any way.
- Online provider assessment with no office visit required
- GLP-1 prescriptions in injection or tablet form, shipped to you
- Free provider visits and unlimited coaching included, no membership fee
If the Bridge’s criteria don’t match your situation, or you’d simply rather handle this through telehealth, you can see our current plans and get started at Legacy Meds.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
FAQ
Is there any weight loss drug that Medicare will pay for?
Yes. As of July 1, 2026, Medicare covers Foundayo, Wegovy (injection and tablet), and Zepbound (KwikPen only) through the Medicare GLP-1 Bridge for beneficiaries who meet BMI and comorbidity criteria. Coverage outside this list still depends on your diagnosis and your Part D plan’s standard formulary rules.
Will Medicare pay for GLP-1 drugs in 2026?
Yes, starting July 1, 2026, through the Medicare GLP-1 Bridge demonstration, which runs through December 31, 2027. Eligibility depends on your BMI, specific health conditions, and your Part D plan type, as detailed in Medicare’s Bridge program materials.
How much does Ozempic cost if you have Medicare Part D?
Ozempic isn’t included in the Medicare GLP-1 Bridge’s covered drug list, so its cost depends entirely on your individual Part D plan’s formulary tier and cost-sharing rules rather than the Bridge’s flat copay. For eligible Bridge drugs like Foundayo, Wegovy, or Zepbound KwikPen, the copay is a flat $50 per month regardless of your benefit phase.
How do I get Medicare to pay for Wegovy?
You’ll need to meet the Bridge’s BMI and comorbidity criteria, be enrolled in an eligible Part D plan type, and have your provider submit a prior authorization confirming you meet those clinical requirements and are participating in a lifestyle program. Once approved, your authorization for Wegovy stays valid through December 31, 2027, as long as you remain on the same drug.
What is the Medicare GLP-1 Bridge copay, and does it count toward my deductible?
The copay is a flat $50 for a one-month supply, and it stays the same regardless of which phase of your Part D benefit you’re in. This amount does not count toward your Part D deductible or your True Out-of-Pocket (TrOOP) costs, and Extra Help does not reduce it.